Azurity Company Profile
✉ Email this page to a colleague
What is the competitive landscape for AZURITY, and when can generic versions of AZURITY drugs launch?
AZURITY has thirty-two approved drugs.
There are eighty-six US patents protecting AZURITY drugs.
There are three hundred and forty patent family members on AZURITY drugs in forty-eight countries and forty-one supplementary protection certificates in fifteen countries.
Summary for Azurity
| International Patents: | 340 |
| US Patents: | 86 |
| Tradenames: | 31 |
| Ingredients: | 24 |
| NDAs: | 32 |
| Patent Litigation for Azurity: | See patent lawsuits for Azurity |
Drugs and US Patents for Azurity
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Azurity | XATMEP | methotrexate sodium | SOLUTION;ORAL | 208400-001 | Apr 25, 2017 | RX | Yes | Yes | 9,855,215 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Azurity | EPANED | enalapril maleate | SOLUTION;ORAL | 208686-001 | Sep 20, 2016 | AB | RX | Yes | Yes | 10,154,987 | ⤷ Sign Up | ⤷ Sign Up | |||
| Azurity | EPANED KIT | enalapril maleate | FOR SOLUTION;ORAL | 204308-001 | Aug 13, 2013 | DISCN | Yes | No | 8,778,366 | ⤷ Sign Up | ⤷ Sign Up | ||||
| Azurity | HORIZANT | gabapentin enacarbil | TABLET, EXTENDED RELEASE;ORAL | 022399-002 | Dec 13, 2011 | RX | Yes | No | 8,686,034 | ⤷ Sign Up | ⤷ Sign Up | ||||
| Azurity | EVEKEO ODT | amphetamine sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 209905-004 | Jan 30, 2019 | DISCN | Yes | No | 10,130,580 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Azurity | FIRVANQ KIT | vancomycin hydrochloride | FOR SOLUTION;ORAL | 208910-002 | Jan 26, 2018 | AB | RX | Yes | Yes | 10,959,946 | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| Azurity | KATERZIA | amlodipine benzoate | SUSPENSION;ORAL | 211340-001 | Jul 8, 2019 | RX | Yes | Yes | 10,959,991 | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Azurity
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Azurity | BIDIL | hydralazine hydrochloride; isosorbide dinitrate | TABLET;ORAL | 020727-001 | Jun 23, 2005 | 4,868,179 | ⤷ Sign Up |
| Azurity | EVEKEO ODT | amphetamine sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 209905-005 | Apr 16, 2021 | 10,130,580 | ⤷ Sign Up |
| Azurity | NYMALIZE | nimodipine | SOLUTION;ORAL | 203340-002 | Apr 8, 2020 | 8,517,997 | ⤷ Sign Up |
| Azurity | HORIZANT | gabapentin enacarbil | TABLET, EXTENDED RELEASE;ORAL | 022399-001 | Apr 6, 2011 | 8,048,917 | ⤷ Sign Up |
| Azurity | BIDIL | hydralazine hydrochloride; isosorbide dinitrate | TABLET;ORAL | 020727-001 | Jun 23, 2005 | 6,465,463 | ⤷ Sign Up |
| Azurity | GLIADEL | carmustine | IMPLANT;INTRACRANIAL | 020637-001 | Sep 23, 1996 | 4,757,128 | ⤷ Sign Up |
| Azurity | EDARBI | azilsartan kamedoxomil | TABLET;ORAL | 200796-001 | Feb 25, 2011 | 5,583,141 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for AZURITY drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Oral Solution | 1 mg/mL | ➤ Subscribe | 2018-08-31 |
| ➤ Subscribe | Powder for Oral Solution | 1 mg/mL | ➤ Subscribe | 2016-06-21 |
International Patents for Azurity Drugs
Supplementary Protection Certificates for Azurity Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1718641 | PA2012004 | Lithuania | ⤷ Sign Up | PRODUCT NAME: AZILSARTANUM MEDOXOMILUM; REGISTRATION NO/DATE: EU/1/11/734/001 - EU/1/11/734/011, 2011 12 07, EU/1/11/735/001 - EU/1/11/735/011 20111207 |
| 1718641 | SPC/GB12/028 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTERED: UK EU/1/11/734/001-011 20111209 |
| 0984957 | SPC/GB11/013 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105 |
| 1718641 | C01718641/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: AZILSARTAN MEDOXOMIL; REGISTRATION NO/DATE: SWISSMEDIC 62158 31.08.2012 |
| 0503785 | C300486 | Netherlands | ⤷ Sign Up | PRODUCT NAME: COMBINATIE VAN OLMESARTANMEDOXOMIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, AMLODIPINEBESYLAAT AND HYDROCHLOORTHIAZIDE; NATL REGISTRATION NO/DATE: RVG 106667, RVG 106671-74, RVG 106682-86 20101221; FIRST REGISTRATION: DE 79810.00.00-79814.00.00 20101216 |
| 1718641 | 12C0034 | France | ⤷ Sign Up | PRODUCT NAME: AZILSARTAN MEDOXOMIL ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/11/735/001 20111207 |
| 1718641 | C20120004 00052 | Estonia | ⤷ Sign Up | PRODUCT NAME: EDARBI - ASILSARTAANMEDOKSOMIIL;REG NO/DATE: C(2011) 9280 FINAL 07.12.2011 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
